Trial | NCT04430556  Report issue

Title

Brain Hippocampal Volume Relationship With Anxious Symptoms in Major Depressive Patients
Study on the Brain Hippocampal Volume, Cortisol and C-reactive Protein Levels Relationship With Anxious Symptoms in Major Depressive Patients

  • Phase

    N/A

  • Study Type

    Interventional

  • Status

    Unknown status

  • Study Participants

    30
The objective of this transversal study is to determine if there is a difference in the volume of the hippocampus with the degree of anxiety.
Study Started
Jul 01
2018
Primary Completion
Dec 31
2020
Anticipated
Study Completion
Dec 31
2020
Anticipated
Last Update
Jun 12
2020

Drug Sertraline

Sertraline will be started in all patients, unless it is contraindicated, in this case, Escitalopram will be indicated.

Volumetric changes in response to sertraline or escitalopram Other

Criteria 

Inclusion Criteria:

First-time patients, without prior antidepressant treatment that meet the diagnostic criteria of DSM 5 for major depressive disorder.
Patients who meet the current major depressive disorder criteria in the MINI interview.
Patients who signed the informed consent for the investigation.

Exclusion Criteria:

Patients presenting insufficient data in the MINI interview for current major depression.
Patients diagnosed with intellectual development disorder, by clinic.
Patients with diagnosis of the schizophrenic spectrum, bipolar disorder, autism spectrum disorder, post-traumatic stress disorder and obsessive-compulsive disorder by clinic and / or by the MINI interview.
Patients with contraindications for MRI.
Patients with serious or unstable medical problems.
Patients undergoing some legal procedure.
Patients with difficulties in understanding the interview or completing the assessment instruments.
No Results Posted